About Femasys
Femasys is a company based in Atlanta (United States) founded in 2004. It operates as a Direct-to-Consumer (D2C) and HealthTech. Femasys has raised $69.22 million across 17 funding rounds from investors including Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC. The company has 71 employees as of December 31, 2024. Femasys offers products and services including FemaSeed, FemVue, FemBloc, and FemCerv. Femasys operates in a competitive market with competitors including Daré Bioscience, Aindra, MTM Laboratories, Teal Health and Aspivix, among others.
- Headquarter Atlanta, United States
- Employees 71 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Femasys Inc.
-
Annual Revenue
$1.63 M (USD)51.97as on Dec 31, 2024
-
Net Profit
-$18.82 M (USD)-32.07as on Dec 31, 2024
-
EBITDA
-$16.91 M (USD)-24.36as on Dec 31, 2024
-
Total Equity Funding
$69.22 M (USD)
in 17 rounds
-
Latest Funding Round
$8.03 M (USD), Post-IPO
Nov 07, 2025
-
Investors
Salem Partners
& 2 more
-
Employee Count
71
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Femasys
Femasys is a publicly listed company on the NASDAQ with ticker symbol FEMY in USA, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Femasys
Femasys offers a comprehensive portfolio of products and services, including FemaSeed, FemVue, FemBloc, and FemCerv.
Innovative solution for infertility treatment in women provided.
Diagnostic tool for infertility assessment in women offered.
Permanent birth control solution for women is developed.
Tool for cervical cancer diagnosis in women provided.
People of Femasys
Unlock access to complete
Funding Insights of Femasys
Femasys has successfully raised a total of $69.22M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $8.03 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Femasys
Femasys has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of targeted therapeutics for cancer and diabetes
|
Locked | Locked | Locked | |
|
Regional investment bank
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Femasys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Femasys
Investment portfolio details for Femasys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Femasys
Detailed financials for Femasys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Femasys Comparisons
Peer comparison for Femasys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Femasys
Femasys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Aindra, MTM Laboratories, Teal Health and Aspivix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| Locked | Locked | Locked |
AI-powered systems for cervical cancer detection are provided.
|
|
| Locked | Locked | Locked |
In vitro diagnostics for early cervical cancer detection are manufactured.
|
|
| Locked | Locked | Locked |
Cervical cancer screening kits are provided by Teal Health.
|
|
| Locked | Locked | Locked |
A next-generation suction-based cervical device for gynecology is provided.
|
Detailed competitors of Femasys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Femasys
Complete news archive for Femasys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Femasys
Femasys was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Femasys is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Femasys is a funded company, having raised a total of $69.22M across 17 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Femasys is 71.
Annual revenue of Femasys is $1.63M as on Dec 31, 2024.
Femasys is engaged in creating next-generation medical devices and solutions targeting underserved areas in womens health. The company is dedicated to addressing critical needs in infertility, birth control, and cancer diagnosis. Products such as FemaSeed, FemVue, and FemBloc are developed to provide transformative healthcare options. Safety and high standards of care are prioritized in all offerings. The focus is maintained on global unmet needs within the healthcare sector for women.
Femasys's top competitors include Daré Bioscience, Aindra and Teal Health.
Femasys offers FemaSeed, FemVue, FemBloc, and FemCerv.
Yes, Femasys is publicly traded on NASDAQ under the ticker symbol FEMY.
Femasys has 3 investors. Key investors include Salem Partners, PharmaCyte Biotech, and Legacy Capital Advisors, LLC.
The ticker symbol of Femasys is FEMY on NASDAQ.